
|Articles|November 1, 2012
Clarifying meaningful use stage 2 now that CMS has announced its final rule
Dermatologists and other eligible professionals (EPs), eligible hospitals and critical access hospitals (CAHs) can now review the upcoming meaningful use stage 2 requirements, now that the Centers for Medicaid and Medicare Services has announced its "final rule" for attestation of meaningful use (MU) stage 2.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
2
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
Introducing Dermatology Times NP/PA Connect
5











